knowledge -WSS

knowledge

author：focus 2025-09-30 16:29:34 - browse：32

Vir Biotechnology said Thursday that a long-acting antibody drug designed to protect healthy individuals from influenza A failed to do so in a nearly 3,000-person clinical trial.

Volunteers who received the highest dose of the drug, known as VIR-2482, were only 16% less likely than the placebo group to develop symptomatic influenza A infections, as defined by trial criteria, over a seven-month period. The difference was not statistically significant.

The results are a setback in broader efforts to develop better protective measures against both seasonal and potential pandemic influenza strains. In the short term, Vir and outside experts hoped VIR-2482 could provide additional annual protection for at-risk groups like older adults, as flu vaccines are often only modestly effective.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Senate panel puts off hardest PBM reforms for another day

WSS

Abridge raises $150m as clinical notes automation market heats up

Weight loss drugs aren’t covered by Obamacare. That may change

Abridge raises $150m as clinical notes automation market heats up

How doctors’ personal politics affect patients

Russian fighter jet damages US Reaper drone with flare over Syria: Officials

Will the FTC rein in IQVIA's health data empire?

focus

knowledge

focus

Tori Bowie and the unacceptable rates of Black maternal death

The haunting brain science of long Covid

FDA approval of Sarepta Duchenne genetic therapy gives me hope

US economic growth accelerated in 2nd quarter, exceeding expectations and quieting recession fears

After affirmative action ruling, medical educators look to 'holistic review'

Weight loss drugs aren’t covered by Obamacare. That may change

Hepatitis C has a cure — but many Americans still lack access to it

US economic growth accelerated in 2nd quarter, exceeding expectations and quieting recession fears

New air purifier tech could be key to improving indoor air quality

As AI regulations shape up, health tech startups beg for clarity

leisure time

Roche’s Alnylam deal shows drug firms interested in heart drugs

FDA warns medical device makers about rise in fabricated data

Roche’s Alnylam deal shows drug firms interested in heart drugs

Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

New CMS data security rules will hurt Medicare, Medicaid research

hotspot

knowledge

hotspot

focus